The current proposal aims to directly compare the psychotherapy and medication treatments for PTSD considered to have the most evidence for effectiveness. While both SSRI and PE have demonstrated efficacy, there are significant individual differences in clinical responses to both treatments. To achieve best clinical outcomes and to utilize available treatment most effectively, it is critical to examine how PTSD and related psychopathology and functional impairment change with these treatments alone and in combination. Further, in order to inform clinical practice, we plan to examine psychological and neurobiological predictors of response to treatment and mechanisms of change during treatment (pre to post treatment change) based on previously identified predictors, including emotion regulation and processing with fMRI in response to emotional challenge tasks, DNA and mRNA (pre and post treatment), and cortisol response to awakening. Start-up activities were completed in 2012Q1 and the primary activity and focus is this year has been on recruitment. To date, we have recruited and randomized 45 Veterans.

关键词：医药；治疗技术；创伤后应激障碍；临床医学；军事人员

查看摘要 索取原文[8页]

Xavier University of Louisiana is in the unique position of developing capability in drug discovery especially in the areas of cancer and health disparities. A significant proportion of the funded research on Xavier s campus including collaborative projects involving Tulane University are related to cancer, drug design, synthesis, and drug delivery. This project expands the partnership between Xavier University and Tulane Cancer Center to develop and validate drugs for breast cancer therapy. The Drug Design Team at Xavier consists of experts in computer aided drug design methods and synthesis and has formed a productive partnership with the Cancer Drug Validation Team at the Tulane Cancer Center. This inter-university collaboration involves training Xavier researchers, including undergraduate students, to carryout the experiments necessary to determine if new compounds would be suitable as new drugs to treat breast cancer. Three separate studies are ongoing as subprojects: (1) Design and synthesis of novel ceramide analogs that potentially reverse chemotherapy drug resistance, (2) Design and synthesis of small molecule inhibitors of HER2 tyrosine kinase to suppress tumorigenesis, and (3) Identification of compounds with the potential for estrogen receptor activity.

关键词：医药；治疗技术；乳腺癌；医学研究；磷转移

查看摘要 索取原文[24页]

Dissemination and metastasis of tumor cells are major causes of morbidity and mortality in breast cancer patients. Therefore it is of vital importance to identify druggable targets to inhibit breast tumor invasion and metastasis. A critical component in the invasive growth, dissemination, and metastasis of cancer is acquisition of motility by tumor cells. Our preliminary studies suggest a novel role for the thromboxane A2 receptor (TP) in controlling breast tumor cell motility via regulating cytoskeleton reorganization. The objective of this proposal is to define the function of TP in tumor cell motility and to validate TP as a target for anti-metastasis therapy of breast cancer. In the first aim, the role of TP in breast tumor cell motility will be determined in the presence or absence of TP activation or inhibition. The isoform(s) of TP involved in tumor cell contraction and motility will be identified in the second specific aim. In the third aim, an orthotopic mouse model will be used to assess whether TP can be targeted to reduce breast cancer metastasis. The proposed studies will be highly significant toward the goals of developing mechanism-based interventions for cancers.

关键词：医药；治疗技术；乳腺癌；抗转移治疗；G蛋白偶联受体

查看摘要 索取原文[20页]

The goal of this research is to firmly establish the mechanism of androgen receptor (AR)-JunD heterodimer induction of the SSAT gene leading to oxidative stress that contributes to the development and progression of prostate cancer (PCa), and to identify small molecules that specifically inhibit this AR-JunD interaction and prevent development/progression of PCa in pre-clinical models. Data from this research will identify the most efficacious drug to be further developed in preclinical toxicity testing and clinical trials for PCa that fall beyond the scope of this proposal. Significant findings during Year 2 of the research include: identification of two non- antiandrogenic AR-JunD inhibitors that significantly inhibit ROS production and androgen-dependent and -independent growth in PCa cells; and determination that the lead compound is orally bioavailable and therefore a promising clinical drug candidate to be further tested for efficacy against preclinical animal models of PCa as proposed.

关键词：医药；治疗技术；前列腺癌；临床试验；基因；抑制剂

查看摘要 索取原文[12页]

This Synergistic IDEA project seeks to develop a novel strategy to effectively target ErbB2-overexpressing breast cancer with anti-ErbB2 antibody coated nanogels carrying potent chemotherapeutics in combination with HSP90 inhibitors to enhance the endocytosis of ErbB2-receptor bound nanogel cargo. A successful outcome of our studies will provide a new therapeutic approach against a particularly difficult form of breast cancer and may provide a template for therapeutic targeting of other forms of breast cancer and other cancers. Success in preclinical models would also provide strong rationale for clinical translation of this technology with the ultimate goals of selective delivery of imaging and therapeutic modalities to tumors. Robust procedures for the synthesis of nanogels were developed, key structural parameters of block copolymers governing the physicochemical properties of the nanogels were identified, nanogels loaded with combination of anticancer therapeutics and methods for the preparation of ErbB2-targeted nanogels were developed, Mannose functionalized BICs provided a safe and stable platform for gene delivery to macrophages, doxorubicin-nanogels showed an efficient systemic drug delivery to human tumor xenografts.

关键词：医药；治疗技术；乳腺癌；纳米丰胸癌症治疗；临床医学

查看摘要 索取原文[13页]

关键词：医药；治疗技术；PTEN基因；前列腺癌

查看摘要 索取原文[22页]

There is no difference in the rate of return to spontaneous circulation between treatment with epinephrine versus glucagon or glucagon plus epinephrine. 24 female swine 30-50kg were sedated with IV anesthesia, and instrumented (continuous aortic diastolic pressure via Millar transducer and Swan-Ganz catheter placed in pulmonary artery). Endotracheal tube was clamped. Four minutes post loss of arterial pressure, CPR was initiated via LUCAS device. We were able to create a reproducible model of asphyxia arrest. We were able to show that an active mechanical compression device (specifically LUCAS device) can provide adequate coronary perfusion pressure and there is no significant difference in CPP in relation to pig weight. We detected the ventricular fibrillation was the most common rhythm after asphyxial cardiac arrest This rhythm then degraded to asystole or bradystole.

关键词：医药；治疗技术；心血管系统；胰高血糖素；肾上腺素

查看摘要 索取原文[5页]

Effective treatment of sensory neuropathies in peripheral neuropathies and spinal cord injury (SCI) is one of the most difficult problems in modern clinical practice. Cell therapy to release antinociceptive agents near the injured spinal cord is a logical next step in the development of treatment modalities. But few clinical trials, especially for chronic pain, have tested the potential of transplant of cells to treat chronic pain. Cell lines derived from the human neuronal NT2 cell line parentage, the hNT2.17 and hNT2.19 lines,which synthesize and release the neurotransmitters gamma- aminobutyric acid (GABA) and serotonin (5HT), respectively, have been used to evaluate the potential of cell-based release of antinociceptive agents near the lumbar dorsal (horn) spinal sensory cell centers to relieve neuropathic pain after PNS (partial nerve and diabetes-related injury) and CNS (spinal cord injury) damage in rat models. Both cell lines transplants potently and permanently reverse behavioral hypersensitivity without inducing tumors or other complications after grafting. Functioning as cellular minipumps for antinociception, human neuronal precursors, like these NT2-derived cell lines, would likely provide a useful adjuvant or replacement for current pharmacological treatments for neuropathic pain.

关键词：医药；治疗技术；中枢神经系统；SCI（脊髓损伤）；细胞治疗

查看摘要 索取原文[33页]

《经济日报》、《每日经济新闻》综合报道，根据食药监总局2月7日发布的《创新医疗器械特别审批程序（试行）》（以下简称《特别审批程序》），自2014年3月1日起，食品药品监管部门对符合相应条件的医疗器械按该程序实施审评审批。对于经审查同意按特别程序审批的创新医疗器械，各级食品药品监督管理部门及相关技术机构，将根据各自职责和该程序规定，按照早期介入、专人负责、科学审批的原则，在标准不降低、程序不减少的前提下，对创新医疗器械予以优先办理，并加强与申请人的沟通交流。

关键词：医药行业；要闻综述

查看摘要 索取原文[10页]

Colorectal cancer (CRC) represents a major health burden, and is the third leading cause of cancer deaths in the U.S. In the past decade, the median survival among patients with metastatic CRC has significantly improved, primarily due the development of active chemotherapeutic regimens that include biological agents. However, despite this success, patients soon run out of therapeutic options and receive salvage therapy that results in only a few weeks of disease stability. We have proposed to employ a team science, systems biology based approach to rapidly identify novel anti-cancer agents and individualize therapeutic strategies in preclinical CRC models. In this Year 1 Progress report, we will present the tasks and key accomplishments achieved within this period of time. In brief, we have completed in vitro testing on a large panel of CRC cell lines for six novel anti-cancer agents. We have completed baseline gene expression profiling of our CRC cell lines panel and patient-derived CRC tumor explant models by high-throughput RNA sequencing approach. We have initiated the in vivo cell line derived xenograft models to test the efficacy of these novel anti-cancer agents and in the process of determining the down stream effectors of these targets by immunoblotting assays. Our research findings for RNA-seq analysis will be presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland (November 6-9, 2012). In summary, we have accomplished all the tasks that we proposed in year 1.

关键词：医药；治疗技术；结肠癌；药物化疗

查看摘要 索取原文[14页]